VIDEO: First-line venetoclax-ibrutinib ‘a win on all fronts’ in CLL
ORLANDO — An all-oral combination of venetoclax plus ibrutinib in the frontline setting was well tolerated and associated with high rates of undetectable minimal residual disease in the blood and bone marrow of patients with chronic lymphocytic leukemia after 1 year of therapy, according to results of the phase 2 CAPTIVATE trial presented at the ASH Annual Meeting and Exposition.
In this video, study coauthor Ryan W. Jacobs, MD, principal investigator of clinical trials for CLL at Atrium Health’s Levine Cancer Institute, discusses results of the trial, which included 164 treatment-naive patients aged 70 years and younger. He told Healio that adding venetoclax (Venclexta; AbbVie, Genentech) to ibrutinib (Imbruvica; Pharmacyclics, Janssen) after a 3-month lead-in with the agent did not result in significant additive toxicities, and the combination was “more effective than anything we have been able to achieve previously with more toxic chemoimmunotherapy combinations.”
“Of course being two oral agents, it is easily administered,” Jacobs said. “So, this is a win on all fronts for CLL patients.”
The researchers will continue evaluating patients enrolled in the CAPTIVATE trial to investigate time-limited treatment options and whether it is safe to stop treatment in patients who achieve MRD negativity.
“I do think ultimately, as is reflected by the number of presentations looking at BTK and BCL-2 inhibition, that we are going to ultimately get a practice-changing paradigm shift in terms of how we are managing CLL based on the success of this combination,” he said.
Tam CS, et al. Abstract 35. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.
Disclosure: Jacobs reports serving as a consultant for AbbVie, Gilead and Juno Therapeutics. He also reports receiving speaker’s bureau fees from AbbVie, AstraZeneca, Genentech and Pharmacyclics LLC; honoraria from TG Therapeutics; and research funding from Pharmacyclics LLC and TG Therapeutics.